NO20006113L - Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer - Google Patents

Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer

Info

Publication number
NO20006113L
NO20006113L NO20006113A NO20006113A NO20006113L NO 20006113 L NO20006113 L NO 20006113L NO 20006113 A NO20006113 A NO 20006113A NO 20006113 A NO20006113 A NO 20006113A NO 20006113 L NO20006113 L NO 20006113L
Authority
NO
Norway
Prior art keywords
cyclosporins
treatment
autoimmune diseases
inflammatory autoimmune
inflammatory
Prior art date
Application number
NO20006113A
Other languages
English (en)
Other versions
NO20006113D0 (no
Inventor
Peter Hiestand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20006113D0 publication Critical patent/NO20006113D0/no
Publication of NO20006113L publication Critical patent/NO20006113L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20006113A 1998-06-02 2000-12-01 Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer NO20006113L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811854.0A GB9811854D0 (en) 1998-06-02 1998-06-02 Organic compounds
PCT/EP1999/003770 WO1999062540A1 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Publications (2)

Publication Number Publication Date
NO20006113D0 NO20006113D0 (no) 2000-12-01
NO20006113L true NO20006113L (no) 2001-01-25

Family

ID=10833083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006113A NO20006113L (no) 1998-06-02 2000-12-01 Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer

Country Status (17)

Country Link
EP (1) EP1082130A1 (no)
JP (2) JP4523154B2 (no)
KR (1) KR20010043969A (no)
CN (1) CN1304315A (no)
AU (1) AU750422B2 (no)
BR (1) BR9910860A (no)
CA (1) CA2333315A1 (no)
GB (1) GB9811854D0 (no)
HU (1) HUP0102142A3 (no)
ID (1) ID27576A (no)
IL (1) IL139589A0 (no)
NO (1) NO20006113L (no)
PL (1) PL344451A1 (no)
SK (1) SK18142000A3 (no)
TW (2) TWI250022B (no)
WO (1) WO1999062540A1 (no)
ZA (1) ZA200006464B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512436A (ja) 1999-10-27 2003-04-02 アレクサンドラ ルーカス、 移植片拒絶を防止及び治療するための組成物及び方法
WO2002026245A2 (en) * 2000-09-29 2002-04-04 Zhong Z Robert Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
CN1964735A (zh) * 2004-04-08 2007-05-16 诺瓦提斯公司 环孢菌素用于治疗脑局部缺血以及脑和脊髓损伤的用途
US7671017B2 (en) 2004-07-14 2010-03-02 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
JP4892486B2 (ja) * 2004-10-01 2012-03-07 デビオファーム ソシエテ アノニム Ｃ型肝炎感染の治療のための［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンの使用、及び当該［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンを含む医薬組成物
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
CN101084005A (zh) * 2004-12-23 2007-12-05 诺瓦提斯公司 用于黄病毒科治疗的化合物
US7897565B2 (en) * 2004-12-23 2011-03-01 Novartis Ag Compositions for HCV treatment
WO2006138507A1 (en) * 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
EP2280989B1 (en) * 2008-06-06 2016-02-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
AU2009334790B2 (en) 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
EP2509615A1 (en) * 2009-12-09 2012-10-17 Scynexis, Inc. Novel cyclic peptides
JP2015532277A (ja) 2012-09-29 2015-11-09 ノバルティス アーゲー 環状ペプチドおよび医薬としてのその使用
WO2014063147A1 (en) * 2012-10-19 2014-04-24 Scynexis, Inc. New antiviral macrocycles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281B2 (en) * 1990-11-02 2000-11-22 Novartis AG Cyclosporins
AR006514A1 (es) * 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky

Also Published As

Publication number Publication date
SK18142000A3 (sk) 2001-06-11
KR20010043969A (ko) 2001-05-25
JP2010059177A (ja) 2010-03-18
PL344451A1 (en) 2001-11-05
HUP0102142A2 (hu) 2001-11-28
GB9811854D0 (en) 1998-07-29
NO20006113D0 (no) 2000-12-01
CA2333315A1 (en) 1999-12-09
TWI250022B (en) 2006-03-01
JP4523154B2 (ja) 2010-08-11
HUP0102142A3 (en) 2001-12-28
TW200522975A (en) 2005-07-16
EP1082130A1 (en) 2001-03-14
IL139589A0 (en) 2002-02-10
ZA200006464B (en) 2002-03-11
ID27576A (id) 2001-04-12
AU4372499A (en) 1999-12-20
WO1999062540A1 (en) 1999-12-09
CN1304315A (zh) 2001-07-18
JP2002516873A (ja) 2002-06-11
BR9910860A (pt) 2001-03-06
TWI250021B (en) 2006-03-01
AU750422B2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
PT1028954E (pt) Imidazoles substituidos uteis no tratamento de doencas inflamatorias
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
PL348059A1 (en) Compounds useful in the treatment of inflammatory diseases
NO20006113D0 (no) Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer
EE9800158A (et) Epinastiin kasutamiseks valude ravis
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
PT946175E (pt) Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
NO20031525L (no) Kjemokinmutanter i behandlingen av multippel sklerose
ID16981A (id) Konsentrat-konsentrat mutiara yang encer
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
HK1025954A1 (en) Triptolide derivatives useful in the treatment of autoimmune diseases
NO965247D0 (no) Anvendelse av kryssbundet hemoglobin ved behandling av subarakuoidalblödning
NO20010044L (no) Anvendelse av texafyriner i makrofag-medierte sykdommer
DE59701536D1 (de) Fibrillationsarmer formkörper
HUP0200354A3 (en) Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri
AU2002300624A1 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
IT1311913B1 (it) Impiego di 6-metilmercaptopurina riboside in composizionioftalmologiche.
ZA987065B (en) Small molecules useful in the treatment of inflammatory disease.
BR7601412U (pt) Aparelho aplicável no tratamento de fluxo de graos em geral
UA3289S (uk) Карта зон інформаційно-хвильових взаємодій на тілі людини
ITSA960002A0 (it) Casco massaggiatore bio - stimolante ad azione antitrofica dell'area fronto - parietale del cuoio capelluto
KR970051648U (ko) 차체의 본네트 구조
SE9703137D0 (sv) Novel treatment of autoimmune diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application